ArticleEpigenetics2014
Deregulation of an imprinted gene network in prostate cancer.
Article in Epigenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05707585 (A Multicenter Study for Evaluating the Benign and Malignant Pulmonary Noldules by Detecting the Epigenetic Imprinting Alterations in Bronchoalveolar Lavage), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Study for Evaluating the Benign and Malignant Pulmonary Noldules by Detecting the Epigenetic Imprinting Alterations in Bronchoalveolar Lavage
Who cites it
34 citing papers in PubMed, 71 citations in OpenAlex.
- IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.Oncogene · 2024Article
- Altered methylation of imprinted genes in neuroblastoma: implications for prognostic refinement.Journal of translational medicine · 2024Article
- [Overexpression of LncRNA MEG3 promotes ferroptosis and enhances chemotherapy sensitivity of hepatocellular carcinoma cells to cisplatin].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: A multi-center study.Cell reports. Medicine · 2023Article
- PLAGL1 is associated with prognosis and cell proliferation in pancreatic adenocarcinoma.BMC gastroenterology · 2023Article
- Molecular Basis of Beckwith-Wiedemann Syndrome Spectrum with Associated Tumors and Consequences for Clinical Practice.Cancers · 2022Review
- The microbiome and prostate cancer.Prostate cancer and prostatic diseases · 2022Review
- The Role of Microbial Factors in Prostate Cancer Development-An Up-to-Date Review.Journal of clinical medicine · 2021Review
- Turkish Validation and Reliability of the EORTC QLQ-CR29 Quality of Life Scale for Colorectal Cancer.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Epigenetics in Prader-Willi Syndrome.Frontiers in genetics · 2021Review
- Novel visualized quantitative epigenetic imprinted gene biomarkers diagnose the malignancy of ten cancer types.Clinical epigenetics · 2020Article
- The Role of Long Non-Coding RNAs in Thyroid Cancer.Frontiers in oncology · 2020Review
- Non-coding RNAs in Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2020Review
- Dysregulation of ncRNAs located at the DLK1‑DIO3 imprinted domain: involvement in urological cancers.Cancer management and research · 2019Review
- A comprehensive overview of genomic imprinting in breast and its deregulation in cancer.Nature communications · 2018Review
- Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.Molecular oncology · 2018Article
- MEG3 inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells.Oncology letters · 2018Article
- Potential applications of MEG3 in cancer diagnosis and prognosis.Oncotarget · 2017Review
- Hypermethylation of NDN promotes cell proliferation by activating the Wnt signaling pathway in colorectal cancer.Oncotarget · 2017Article
- Deregulation of the non-coding genome in leukemia.RNA biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple epigenetic alterations contribute to prostate cancer progression by deregulating gene expression. Epigenetic mechanisms, especially differential DNA methylation at imprinting control regions (termed DMRs), normally ensure the exclusive expression of imprinted genes from one specific parental allele. We therefore wondered to which extent imprinted genes become deregulated in prostate cancer and, if so, whether deregulation is due to altered DNA methylation at DMRs. Therefore, we selected presumptive deregulated imprinted genes from a previously conducted in silico analysis and from the literature and analyzed their expression in prostate cancer tissues by qRT-PCR. We found significantly diminished expression of PLAGL1/ZAC1, MEG3, NDN, CDKN1C, IGF2, and H19, while LIT1 was significantly overexpressed. The PPP1R9A gene, which is imprinted in selected tissues only, was strongly overexpressed, but was expressed biallelically in benign and cancerous prostatic tissues. Expression of many of these genes was strongly correlated, suggesting co-regulation, as in an imprinted gene network (IGN) reported in mice. Deregulation of the network genes also correlated with EZH2 and HOXC6 overexpression. Pyrosequencing analysis of all relevant DMRs revealed generally stable DNA methylation between benign and cancerous prostatic tissues, but frequent hypo- and hyper-methylation was observed at the H19 DMR in both benign and cancerous tissues. Re-expression of the ZAC1 transcription factor induced H19, CDKN1C and IGF2, supporting its function as a nodal regulator of the IGN. Our results indicate that a group of imprinted genes are coordinately deregulated in prostate cancers, independently of DNA methylation changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.